This site is intended for
U.S. healthcare professionals
Enrollment and Prescription Form Available Soon
The Enrollment and Prescription Form is not yet available.
Please check back to download the latest form.
Return to previous page2022 ESC/ERS Guidelines recommend combination therapy to address multiple pathways
The endothelin and nitric oxide pathways are 2 of the current therapeutic targets in PAH1
The 2022 ESC/ERS Guidelines recommend initial combination therapy of an ERA and a PDE5 inhibitor for patients with idiopathic PAH, heritable PAH, PAH-CTD, or drug-associated PAH without cardiopulmonary comorbidities at low or intermediate risk.1
The guidelines include a Class I, Level B recommendation for the combination of macitentan and tadalafil for newly diagnosed patients with PAH (WHO Group I) and patients at follow-up based on risk.1*
- Class I: Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Level B: Data derived from a single randomized clinical trial or large non-randomized studies.
For treating adult patients with
PAH in WHO FC II-III,
OPSYNVI® (macitentan/tadalafil) is the first and only US FDA-approved single-tablet combination of 2 recommended treatments.1-3
Science Liaison (MSL)Contact your MSL
ERA=endothelin receptor antagonist; ERS=European Respiratory Society; ESC=European Society of Cardiology; FC=Functional Class; FDA=US Food and Drug Administration; PAH=pulmonary arterial hypertension; PAH-CTD=PAH associated with connective tissue disease; PDE5i=phosphodiesterase type 5 inhibitor; WHO=World Health Organization.
References: 1. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022;43(38):3618-3731. 2. OPSYNVI® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 3. Grünig E, Jansa P, Fan F, et al. Randomized trial of macitentan/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2024;83(4):473-484.
